FDA Approves Moderna Flu Shot

The FDA cleared Moderna's mRNA flu vaccine, the first of its kind.

•Balanced

First-Ever mRNA Flu Vaccine Finally Approved By FDA In Time For 2026 Season – After They Initially Refused To Review It

Here We Go Again: FDA Approves First-Ever Moderna mRNA Flu Shot, Reportedly With No Key Testing, Worse Safety Than Normal Flu Shots

Opinion | The FDA, Replimune and a New Flu Shot

Articles

Sources

47%

Analysis & opinion

The reporting

A neutral summary of the key facts most outlets agree on, drawn from reporting across the political spectrum.

The FDA approved Moderna’s mFlusiva, the first U.S. seasonal influenza vaccine made with mRNA technology, for adults ages 50 and older. The decision gives full approval for ages 50 to 64 and accelerated approval for adults 65 and older, with Moderna required to run an additional clinical trial in the older group. In a late-stage trial, mFlusiva was about 27% more effective than a standard flu shot, and Moderna expects it to be available for the 2026-2027 flu season.

Analysis & opinion

The arguments that emerged from this coverage — built only from the analysis and opinion pieces, never from straight reporting. Each dot is one article, placed by its outlet's bias — left to right. How to read our graphics →

angles sorted left-argued → right-argued

mRNA flu progressLeans Left

mRNA flu vaccines are a valuable scientific advance that could lead to better protection against influenza. The technology deserves continued research and sound regulation rather than being slowed by political hostility or abandoned before its potential is realized.